- Report
- September 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- January 2026
- 182 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 184 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 196 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 180 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 192 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 188 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 191 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 180 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 488 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 235 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 287 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 291 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 276 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 196 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- October 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP

Etanercept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein that works by blocking the action of tumor necrosis factor (TNF), a protein involved in inflammation. Etanercept is administered by subcutaneous injection and is available in both brand name and generic forms.
Etanercept is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other medications. It is generally well tolerated, with the most common side effects being injection site reactions, headache, and upper respiratory tract infections.
The etanercept market is highly competitive, with several major players. These include Amgen, Pfizer, AbbVie, and Johnson & Johnson. Other companies in the market include Biogen, Merck, and Novartis. Show Less Read more